Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. Biotie is a subsidiary of Acorda Therapeutics, Inc. ("Acorda") and its shares, excluding of those owned by Acorda, are currently subject to a redemption process in accordance with the Finnish Companies Act.

Biotie´s head office is located in Turku, Finland. The company has two operative subsidiaries:
Biotie Therapies Inc, San Francisco, U.S.A and Biotie Therapies AG, Zurich, Switzerland.

Biotie´s objective is to provide every employee with fair treatment, while offering a stimulating and dynamic environment. We are an equal opportunity employer with competitive compensation and a benefits package tailored to local conditions.

Growing together strong leadership, a common set of values and dedicated employees

Updated 30 September, 2016